Background for We Deliver.png

OUR FOCUS

TissueGen is focused on developing advanced drug delivery platforms that answer unmet medical needs in several areas. Our efforts are primarily directed to discovering solutions for unsolved problems in the areas of ophthalmology and neurology, though our proprietary technology can be applied across a broad range of application areas.

Our layered portfolio is composed of both approved medications formulated in a next generation delivery system, as well as novel APIs.

Eye for Our Focus Ophthalmology.png

OPHTHALMOLOGY

Alleviating post-surgical ocular pain and inflammation, reducing treatment burden in wet AMD

Nerve for Our Focus - Neurology.png

NEUROLOGY

Peripheral nerve regeneration

TG-001 – LONG-ACTING, NON-STEROID DELIVERY PLATFORM

We developed a first-to-market, long-acting, non-steroidal anti-inflammatory delivery device to treat post-surgical ocular pain and inflammation. This product will reduce treatment burden through enablement of dropless treatment and has the potential to Improve surgical outcomes. The product offers the following advantages:

 
 

TG-002 – MINIMALLY INVASIVE, LONG-TERM, ANTI-VEGF DELIVERY PLATFORM

We are developing a first-in-class, minimally invasive, long-term anti-VEGF delivery device. Our solution provides the following attributes:

 

TG-003 – FIBER-BASED DELIVERY PLATFORM

Our proprietary fibers deliver sensitive growth factors over an extended period, while retaining bioactivity.

 

TG-004 – OPHTHALMIC NEUROPROTECTION

Strategies that promote neuronal survival for diabetic retinopathy, glaucoma, age-related macular degeneration, and retinitis pigmentosa are lacking. We are developing a long-acting, small molecule delivery device to address the challenge of neuroprotection in the eye, we provide solutions to mitigate vision loss caused by these diseases.

PIPELINE MAP

Product Candidate

Preclinical

GMP

Phase 1/2

Phase 3

TG-001

  • Long-acting, non-steroid delivery platform

  • Treat post-surgical ocular pain and inflammation

TG-002

  • Minimally-invasive, long-term, anti-VEGF delivery platform

  • Provides controlled, local delivery for 6-9 months

TG-003

  • Fiber-based neurotrophic delivery platform

TG-004

  • Secondary Neurodegeneration